Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Stopped early · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Alzheimer's Disease

In brief

The purpose of this Phase 1/Phase 2 study is to evaluate how the body handles the drug and the drug's effect on the body of participants with mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) or mild AD and who test positive for amyloid plaque.

Key facts

Study ID
NCT01561430
Run by
Eli Lilly and Company
People needed
70
Starts
2012-03-01
Expected to finish
2013-08-01
Last updated by the study team
2018-05-18

Who can join

Age: 55 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.